Serum Level of 8-Isoprostane In Oral Erosive Lichen Planus Before and After Treatment With Lycopene: RCT

Serum Level of 8-Isoprostane in Patients with Oral Erosive Lichen Planus Before and After Treatment with Lycopene: A Randomized Controlled Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202003484099670

Enrollment

Registered

2020-03-11

Start date

2019-01-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Health

Interventions

Lycopene

Corticosteroids

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are unresponsive to the conventional topical corticosteroid therapy and in need of systemic oral corticosteroids.

Exclusion criteria

Exclusion criteria: Smoking and tobacco use in any form. Pregnant and lactating females. suspected restoration or drug-related reaction (Lichenoid Contact/Drug reaction). any systemic disease ( Diabetes, liver disease, renal disease, any other autoimmune or collagen disease). cutaneous Lichen Planus (Skin lesions associated with oral lesions). Lesions showing any dysplastic changes in the biopsy specimen. Patients receiving any kind of systemic or local treatment for LP for the past one month.

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale (VAS);serum 8-isoprostane levels	—

Secondary

Measure	Time frame
Clinical score	—

Countries

Egypt

Contacts

Public ContactElsayedamr Basma

Patient Information Manager

elsayedamr@yahoo.com00201223106023

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026